Efficacy and Safety of SGLT2 Inhibitors in Reducing Glycated Hemoglobin and Weight in Emirati Patients With Type 2 Diabetes

Bashier, Alaaeldin; Khalifa, A.; Rashid, Fouzia; Abdelgadir, Elamin; Qaysi, Amina Adil Al; Ali, Razan; Eltinay, Ahmed; Nafach, Jalal; Alsayyah, Fatima; Alawadi, Fatheya

doi:10.14740/jocmr2976w

Cited by 22 publications

(18 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Adding SGLT2 inhibitors in patients receiving first‐line monotherapy resulted in an increase proportion of subjects achieving a HbA1c <7%, with low risk of hypoglycaemic events . In addition to glycaemic control, SGLT2 inhibitors cause a weight reduction of approximately 2 kg already at 6 weeks after initiation of therapy . The most common adverse events include urinary tract infections and vulvovaginitis/balanitis with higher incidence in female than male, which could be linked to an increase urinary glucose excretion and which may limit utilization of this drug in immunocompromised patients …”

Section: Glycosuricsmentioning

confidence: 99%

Safety and efficacy of antihyperglycaemic agents in diabetic kidney disease

Niezen

Castillo

Castaner

et al. 2019

Endocrino Diabet & Metabol

View full text Add to dashboard Cite

Diabetic kidney disease (DKD) is the major contributor to the mortality and the financial burden of diabetes, accounting for approximately 50% of the cases of end‐stage renal disease (ESRD) in the developed world. Several studies have already demonstrated that achieving blood pressure targets in DKD with agents blocking the renin‐angiotensin system confer superior renoprotection when compared to other agents. However, the effects on renal outcomes of antihyperglycaemic agents in these patients have not been reported or studied broadly until recent years. The intent of this article is to review the available data on safety, efficacy, impact on renal outcomes and pathophysiology implications of the most utilized antihyperglycaemic agents in DKD/ESRD.

show abstract

Section: Glycosuricsmentioning

confidence: 99%

Safety and efficacy of antihyperglycaemic agents in diabetic kidney disease

Niezen

Castillo

Castaner

et al. 2019

Endocrino Diabet & Metabol

View full text Add to dashboard Cite

show abstract

“…Likely, the bodyweight also reduced from the baseline at the sixth month, from 85.7±17.8 kg to 84±12.2 kg (p=0.0001). (Bashier et al, 2017)…”

Section: Effects Of Sglt-2 Inhibitorsmentioning

confidence: 99%

A comparative study on the effect of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors as an add on therapy in patients with type 2 DM

Vishnupriya¹,

Andhuvan²,

Saravanan³

et al. 2020

ijrps

View full text Add to dashboard Cite

There were about 65 million diabetic population in 2016 in India. There were studies which concluded that the Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter-2 Inhibitors were providing non-glycaemic control and cardiovascular benefits. Hence, it is important to find out the effect of those drugs on various parameters among the Indian Type 2 Diabetes Mellitus population. The aim is to evaluate and compare the effects of SGLT-2 inhibitors and DPP-4 inhibitors in Type 2 DM patients. The objective is to find out &compare the effects of both class of drugs on the physical profile [Body Weight (BW), Body Mass Index (BMI), Hip-Waist ratio), Diabetic Profile [Fast Blood Sugar (FBS), Glycated Haemoglobin (HbA1C)] & Side Effect Profile. The patients were categorized into two Group 1 & 2. Both groups were containing 50 patients, each based on the inclusion &exclusion criteria. The collection of demographics and history were done. Group 1 patients were initiated with DPP-4 Inhibitor, Group 2 patients with SGLT-2 Inhibitors, respectively. At baseline and during follow-up, the parameters like the physical profile, Diabetic Profile were noted. In Body Weight, the mean difference between the groups was found to be 2.9 ±0.79 (p<0.05). Similarly, for BMI, it was 2.9±1.36 (p<0.04). For the Hip-Waist ratio, it was 0.07 (p<0.05). For FBS, it was 22.08 mg/dl (0.0001), for HbA1c it was 1.09 (p<0.0043). On the Side effect profile, SGLT-2 Inhibitors were showing higher incidence for the occurrence of Urinary Tract Infection (UTI) while comparing with DPP-4 Inhibitors. This can be overcome by proper patient counseling. This study concluded that SGLT-2 inhibitors may serves as the best medication choice for add on therapy in Type 2 DM patients.

show abstract

“…Consequently, SGLT2 inhibitors reduce plasma glucose in an insulin-independent manner and improve insulin resistance in diabetes [22]. SGLT2 inhibitors were shown to reduce glycated haemoglobin (HbA1c) by approximately 0.6%–1.2%, with a lower rate of hypoglycaemia [23]. Four recent major trials have shown that SGLT2 inhibitors are superior to other anti-diabetic medications in the prevention of cardiovascular events and renal protection [5,24,25,26].…”

Section: Reno-cardiovascular Protection Of Sglt2 Inhibitionmentioning

confidence: 99%

The New Era for Reno-Cardiovascular Treatment in Type 2 Diabetes

García-Carro

Vergara

Agraz

et al. 2019

JCM

View full text Add to dashboard Cite

Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease in the developed world. Until 2016, the only treatment that was clearly demonstrated to delay the DKD was the renin-angiotensin system blockade, either by angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. However, this strategy only partially covered the DKD progression. Thus, new strategies for reno-cardiovascular protection in type 2 diabetic patients are urgently needed. In the last few years, hypoglycaemic drugs, such as sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists, demonstrated a cardioprotective effect, mainly in terms of decreasing hospitalization for heart failure and cardiovascular death in type 2 diabetic patients. In addition, these drugs also demonstrated a clear renoprotective effect by delaying DKD progression and decreasing albuminuria. Another hypoglycaemic drug class, dipeptidyl peptidase 4 inhibitors, has been approved for its use in patients with advanced chronic kidney disease, avoiding, in part, the need for insulinization in this group of DKD patients. Studies in diabetic and non-diabetic experimental models suggest that these drugs may exert their reno-cardiovascular protective effect by glucose and non-glucose dependent mechanisms. This review focuses on newly demonstrated strategies that have shown reno-cardiovascular benefits in type 2 diabetes and that may change diabetes management algorithms.

show abstract

Efficacy and Safety of SGLT2 Inhibitors in Reducing Glycated Hemoglobin and Weight in Emirati Patients With Type 2 Diabetes

Cited by 22 publications

References 22 publications

Safety and efficacy of antihyperglycaemic agents in diabetic kidney disease

Safety and efficacy of antihyperglycaemic agents in diabetic kidney disease

A comparative study on the effect of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors as an add on therapy in patients with type 2 DM

The New Era for Reno-Cardiovascular Treatment in Type 2 Diabetes

Contact Info

Product

Resources

About